Deborah Toppmeyer

9.8k citations
94 papers · 3.4k · 2 hit papers · h-index 26

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Cancer-related Molecular Pathways
    • Cancer Treatment and Pharmacology
    • Cancer Cells and Metastasis
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Treatment and Pharmacology 21
    • HER2/EGFR in Cancer Research 16
    • Cancer Immunotherapy and Biomarkers 8
    • Breast Cancer Treatment Studies 28
    • Cancer Genomics and Diagnostics 9

Deborah Toppmeyer

87 papers receiving 3.4k citations

Hit Papers

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study 2018 · 460 citations
4600+6+13Years since publication250500750

Peers

Deborah Toppmeyer
Comparison fields: 5 of 110
  • Oncology 2.3k
  • Cancer Research 1.2k
  • Pathology and Forensic Medicine 388
  • Pulmonary and Respiratory Medicine 678
  • Immunology 367
Replace Gen‐Hong Di with:
Gen‐Hong Di China
Jeremy Braybrooke United Kingdom
Giulia Viale Italy
Stéphanie Lheureux Canada
Robert M. Wenham United States
Min Hee Hur South Korea
Robert J. Goulet United States
Hiroyoshi Doihara Japan
Catriona M. McNeil Australia
Serenella Eppenberger‐Castori Switzerland
Deborah Toppmeyer relative to Gen‐Hong Di China Gen‐Hong Di's profile →
Citations per field
00.5×1.6×
Gen‐Hong Di · 1×
Citations per year

Countries citing papers authored by Deborah Toppmeyer

Since Specialization
Citations

This map shows the geographic impact of Deborah Toppmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Toppmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Toppmeyer more than expected).

Fields of papers citing papers by Deborah Toppmeyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Toppmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Toppmeyer. The network helps show where Deborah Toppmeyer may publish in the future.

Co-authors

The 25 scholars most cited alongside Deborah Toppmeyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Toppmeyer Line = papers co-authored together Deborah Toppmeyer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 94 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Hit paper breakdown →
2006874
2
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Hit paper breakdown →
2018460
3 2006242
4 2015152
5 2017135
6 1994109
7 202198
8 201790
9 202088
10 201779
11
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
199572
12 201470
13 200466
14
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
200261
15 201755
16
Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
199440
17 201732
18 200832
19 199430
20 200929

About Deborah Toppmeyer

Deborah Toppmeyer is a scholar working on Oncology, Cancer Research, Genetics, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 94 papers that have together received 3.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (28 papers), BRCA gene mutations in cancer (23 papers), Cancer Treatment and Pharmacology (21 papers), HER2/EGFR in Cancer Research (16 papers), Advanced Breast Cancer Therapies (14 papers), Cancer Genomics and Diagnostics (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer therapeutics and mechanisms (7 papers). The work is most often cited by research in Oncology (2.3k citations), Cancer Research (1.2k citations), Pathology and Forensic Medicine (388 citations), Pulmonary and Respiratory Medicine (678 citations) and Immunology (367 citations). Deborah Toppmeyer has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Bruce G. Haffty, Thomas Kearney, Qifeng Yang, Michael Reiß, Susan A. Higgins, Joanne B. Weidhaas, Lyndsay N. Harris, Eric P. Winer, Hope S. Rugo and Kim M. Hirshfield. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, International Journal of Radiation Oncology*Biology*Physics, Frontiers in Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact